Literature DB >> 3041856

Human cerebral malaria.

M Aikawa1.   

Abstract

Possible factors contributing to the development of cerebral malaria were discussed based on pathological changes in Burmese patients who died of cerebral malaria. Blockage of cerebral capillaries by Plasmodium falciparum infected erythrocytes appeared to be the principal cause of cerebral malaria. From electron microscopic results, it was concluded that knobs on infected erythrocytes acted as focal junctions which mediated adhesion to endothelial cells. The knobs are, therefore, important contributors to the blockage of the capillary lumen and ensuing pathological changes in cerebral tissues. Host cell molecules such as OKM5 and thrombospondin may function as endothelial cell surface receptors for the attachment of knobs of P. falciparum infected erythrocytes. Immunological events might also play a role in the pathogenesis of cerebral malaria. This was suggested by the presence of IgG, IgM, P. falciparum antigens, and knob proteins in the cerebral capillaries of the people with cerebral malaria. It will be important to assess the candidate malaria vaccines now in development not only for their efficacy in reducing parasitemia but for effects they may have on the sequestration of infected erythrocytes in the brain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3041856     DOI: 10.4269/ajtmh.1988.39.3

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  35 in total

1.  Human cerebral malaria: characterization of malarial antibodies in cerebrospinal fluid.

Authors:  S Mitra; B Ravindran; B K Das; R K Das; P K Das; R N Rath
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  Antibodies to a histidine-rich protein (PfHRP1) disrupt spontaneously formed Plasmodium falciparum erythrocyte rosettes.

Authors:  J Carlson; G Holmquist; D W Taylor; P Perlmann; M Wahlgren
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

3.  Chondroitin-4-sulfate impairs in vitro and in vivo cytoadherence of Plasmodium falciparum infected erythrocytes.

Authors:  B Pouvelle; P Meyer; C Robert; L Bardel; J Gysin
Journal:  Mol Med       Date:  1997-08       Impact factor: 6.354

4.  Multiple adhesive phenotypes linked to rosetting binding of erythrocytes in Plasmodium falciparum malaria.

Authors:  V Fernandez; C J Treutiger; G B Nash; M Wahlgren
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Tumor necrosis factor production by human macrophages stimulated in vitro by Plasmodium falciparum.

Authors:  S Picot; F Peyron; J P Vuillez; G Barbe; K Marsh; P Ambroise-Thomas
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

6.  Ultrastructure of rosette formation by Plasmodium coatneyi-infected erythrocytes of rhesus.

Authors:  T Tegoshi; R Udomsangpetch; A Brown; S Nakazawa; H K Webster; M Aikawa
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

7.  Short-chain aliphatic polysulfonates inhibit the entry of Plasmodium into red blood cells.

Authors:  Robert Kisilevsky; Ian Crandall; Walter A Szarek; Shridhar Bhat; Christopher Tan; Lee Boudreau; Kevin C Kain
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Evolutionary genetic insights into Plasmodium falciparum functional genes.

Authors:  Meenu Sharma; Aditya P Dash; Aparup Das
Journal:  Parasitol Res       Date:  2009-11-10       Impact factor: 2.289

9.  Cytoadherence characteristics of rosette-forming Plasmodium falciparum.

Authors:  R Udomsangpetch; H K Webster; K Pattanapanyasat; S Pitchayangkul; S Thaithong
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

10.  Plasmodium falciparum-infected erythrocytes do not adhere well to C32 melanoma cells or CD36 unless rosettes with uninfected erythrocytes are first disrupted.

Authors:  S M Handunnetti; T H Hasler; R J Howard
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.